Beyond the Hype: Can Hard Science Redefine How We Get Older?

IRVINE, CA – August 20, 2026 – Each year, the South by Southwest (SXSW) festival in Austin becomes a global barometer for what’s next in technology and culture. For 2027, a new, fundamental question is vying for the main stage: "Can We Get Better at Aging?" This isn't just a philosophical debate; it's the title of a proposed panel featuring some of the leading minds in restorative medicine, including Dr. Hans Keirstead, the chairman of biotechnology firm Immunis, Inc.

The nomination places the complex, often-sensationalized world of longevity science squarely at the intersection of tech, health, and public fascination. As our global population ages, the conversation is shifting from simply extending lifespan to enhancing healthspan—the period of life spent in good health. Dr. Keirstead's inclusion in this potential discussion highlights a critical pivot in the field: a move away from speculative anti-aging claims and toward measurable, science-backed therapies designed to restore the body’s innate functions.

A New Blueprint for Longevity

For decades, medicine has focused on managing the effects of aging—treating chronic diseases, alleviating symptoms, and compensating for lost function. The new frontier, championed by companies like Immunis, is built on a different premise: restoration. The goal is no longer just to slow the decline, but to help the body actively repair and rebuild itself.

At the heart of this approach is a technology that sidesteps one of the most complex issues in regenerative medicine: the use of live stem cells. Immunis is developing what it calls “cell-free, cell therapies.” Its lead candidate, IMM01-STEM, is a biologic derived from the secretome of stem cells. In simple terms, the company harvests the powerful signaling molecules—proteins, lipids, and other factors—that stem cells naturally secrete to communicate with and orchestrate the body’s repair mechanisms.

This secretome is then formulated into an off-the-shelf therapy. The key advantage, according to researchers, is that it delivers the therapeutic benefits of stem cell-derived factors without the risks associated with administering live cells, such as immune rejection or uncontrolled growth. The therapy is designed to provide a balanced cocktail of regenerative signals that can reduce chronic inflammation and encourage native cells to function more youthfully. For Immunis, the primary target is sarcopenia—age-related muscle loss—a condition that quietly chips away at strength, mobility, and independence.

"The conversation around longevity has never been more important—or more crowded," says Dr. Keirstead. "People are inundated with promises about reversing aging, yet very few approaches are supported by rigorous clinical evidence."

The Data That Defines the Debate

Dr. Keirstead's emphasis on "rigorous clinical evidence" is more than just a talking point; it's a direct challenge to a market flooded with hype. The credibility of this new restorative approach hinges on data, and Immunis has begun to release promising, if early, results.

In January 2026, the company announced positive topline interim data from its Phase 2 STEM-META study, a double-blind, placebo-controlled trial involving obese seniors with muscle weakness. The results showed that subjects treated with IMM01-STEM experienced a 26% improvement in gait speed compared to the placebo group. The absolute improvement of 0.16 meters per second three months after treatment surpassed the 0.1 m/s threshold considered clinically meaningful for quality-of-life improvements. Gait speed is a critical vital sign in geriatrics, often predictive of overall health, fall risk, and mortality.

These findings build on a completed Phase 1/2a trial that evaluated the therapy in elderly individuals with both sarcopenia and knee osteoarthritis. That study reported no serious adverse events related to the treatment and pointed to significant quality-of-life improvements related to pain, stiffness, and physical function. Preclinical studies published in peer-reviewed journals like GeroScience and Aging Cell have further shown that the therapy increased lean mass, reduced fat, and improved glucose tolerance in aged animal models. With Investigational New Drug (IND) applications approved by the FDA for its trials, the company is moving its platform through the established regulatory framework required to prove safety and efficacy.

An Architect of the Approach

Navigating the treacherous waters between hope and hype requires a steady hand, and Dr. Hans Keirstead's career suggests he is well-suited for the task. Before chairing Immunis, he was a renowned stem cell expert and a Full Professor at the University of California, Irvine, for 15 years. There, he founded and directed the university's $77 million stem cell research center and secured over $16 million in research grants.

His work has led to therapies for spinal cord injury, multiple forms of cancer, and immune disorders. A serial entrepreneur, Dr. Keirstead has founded five biotech companies, three of which were successfully acquired by major pharmaceutical firms, including one whose technology was sold to Bristol Myers Squibb. He was also a founding advisor to the California Stem Cell Initiative (CIRM), which established a multi-billion-dollar fund for regenerative medicine research. His long history of translating lab discoveries into clinical programs provides a foundation of credibility that is essential in the high-stakes longevity sector.

"The future of healthy aging should be built on science that is measurable, reproducible, and focused on restoring quality of life," Dr. Keirstead stated, underscoring his mission to prioritize responsible innovation that can build trust in this next generation of medicine.

Where Culture and Clinical Science Converge

The potential for this discussion to unfold at SXSW is significant. Unlike a traditional medical conference, SXSW attracts a diverse audience of technologists, investors, artists, and policymakers. The panel selection itself is a democratic process, driven by public voting on the SXSW PanelPicker platform until August 23. The nomination of a topic as scientifically dense as restorative medicine signals a growing public appetite for understanding the technologies that will shape the future of human health.

Bringing this conversation to a cultural hub like Austin provides a unique opportunity to demystify the science and engage in a broader dialogue about its ethical and societal implications. The proposed panel, which also includes experts on heart and brain health, aims to present a holistic view of restorative aging. For a company like Immunis, it's a chance to build a narrative grounded in data and differentiate its methodical, clinical approach from the unproven shortcuts that often dominate headlines. This convergence of hard science and popular culture may be exactly what's needed to move the needle on how we, as a society, prepare to not just live longer, but live better.